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Disseminated metastatic breast cancer needs aggressive treatment due to its reduced response to anticancer treatment and hence
low survival and quality of life. Although in theory a combination drug therapy has advantages over single-agent therapy, no
appreciable survival enhancement is generally reported whereas increased toxicity is frequently seen in combination treatment
especially in chemotherapy. Currently used combination treatments in metastatic breast cancer will be discussed with their
challenges leading to the introduction of novel combination anticancer drug delivery systems that aim to overcome these
challenges. Widely studied drug delivery systems such as liposomes, dendrimers, polymeric nanoparticles, and water-soluble
polymers can concurrently carry multiple anticancer drugs in one platform. These carriers can provide improved target speciﬁcity
achieved by passive and/or active targeting mechanisms.
1.Introduction
Breast cancer is the most common cancer in females and
the second most common cause of death in women in
the United States [1]. Metastatic breast cancer is the most-
advanced stage of breast cancer involving the dissemination
of cancerous cells from the breast to other areas of the
body. At the time of diagnosis, less than 10% of women
are presented with a metastatic disease. However, when
relapse occurs after deﬁnitive therapy for early stage or
locally advanced disease, the majority of patients end up
with disseminated metastases rather than an isolated local
recurrence. The median survival for metastatic breast cancer
patients appears to have improved over time, which has
been attributed to the availability of new more eﬀective
agents, including taxanes, aromatase inhibitors, and anti-
HER2 agents [2, 3]. However, metastatic breast cancer is
unlikely to be completely cured and the survival is extremely
low as ﬁve-year survival is attained in only 23.4% of these
patients.Thereforeitisimportanttounderstandthepatients’
treatmentgoalsandtheneedforaggressivetherapyincluding
combination therapy [4]. The primary goals of systemic
treatment of metastatic breast cancer are prolonged survival,
alleviated symptoms, and maintained or improved quality
of life despite the toxicity associated with treatment [5–8].
Althoughcombiningchemotherapy,biologictherapy,and/or
endocrine therapy might have additive and even synergistic
eﬃcacy in theory, it generally leads to increased toxicity.
Clinical trials have failed to show a clear survival advantage
for the concurrent administration of chemotherapy and
endocrine therapy over either single modality [5, 9, 10].
Novel biologic therapies, that speciﬁcally target molecular
pathways, such as angiogenesis (growth of new blood vessels
from preexisting vessels especially around tumors) and other
growth factors relevant to the development of breast cancer,
have contributed to advancing the treatment and improving
the prognosis of metastatic breast cancer. Noncytotoxic
biological agents act on speciﬁc molecular pathways to target
cancer cells while sparing normal tissues, and therefore
do not generally cause alopecia, vomiting, and myelosup-
pression that are characteristic of cytotoxic drugs. New
agents and combination regimens clearly have the potential
to signiﬁcantly improve clinical outcomes, yet they also
create new challenges including limited patient population,2 Journal of Drug Delivery
tolerability, and compliance issues [11]. Over the last decade,
carrier-mediated drug delivery systems such as liposomes,
dendrimers, nanoparticles, water-soluble polymer-drug, and
polymer-protein conjugates have emerged as a new class
of antitumor agents [12–14]. The advantages of carrier-
mediated drug delivery over conventional anticancer therapy
include:(1)passivetumortargetingduetotheenhancedper-
meabilityandretention(EPR)eﬀect[15],(2)activetargeting
by additionally introducing receptor speciﬁc ligands to the
carriers [12], (3) lower toxicity of bound or encapsulated
drug [16], and (4) intracellular endocytotic uptake with
the potential to bypass mechanisms of drug resistance,
including p-glycoprotein-mediated multidrug eﬄux [13].
Drug delivery systems derived from liposomes, dendimers,
polymeric nanoparticles and micelles are currently under
preclinical and clinical development as novel nanomedicines
that can deliver a combination of multiple drugs to various
cancers. The present paper highlights the currently available
combination therapy approaches including emerging novel
carrier-mediated drug delivery systems with an emphasis on
metastatic breast cancer.
2. Combination Therapy in
MetastaticBreast Cancer
For better therapeutic eﬀectiveness combination anticancer
treatment has long been adopted in clinics. The general
rationale for employing combination therapy is twofold.
First, when multiple drugs with diﬀerent molecular targets
are applied, the cancer adaptation process such as cancer
cell mutations can be delayed. Second, when multiple
drugs target the same cellular pathway they could function
synergistically for higher therapeutic eﬃcacy and higher
target selectivity. Currently available combination regimens
for metastatic breast cancer in clinics are limited to admin-
istrating a physical mixture of two or more anticancer
agents. The clinically used combination regimens in the
US can be broadly classiﬁed based on their mechanisms of
action (Figures 1(a) and 1(b)) including: (1) combination
of nonspeciﬁc small molecule chemotherapeutic agents, (2)
combination of target-speciﬁc biologic agent and small
molecule chemotherapeutic agents, and (3) combination of
target-speciﬁc biologic agents.
2.1. Combination of Nonspeciﬁc Small Molecule Chemothera-
peutic Agents. Small molecule chemotherapeutic agents can
be given singly or in combination (Figure 1(a)). Toxicity
is typically less with single-agent therapy and quality of
life appears better. However, combination therapy may
be a more appropriate ﬁrst-line choice for symptomatic
patients or those with rapidly progressive visceral metastases
because of the greater likelihood of an objective response.
Of the many active combination chemotherapy regimens
in metastatic breast cancer (Table 1), none is established as
the optimal ﬁrst-line regimen. For example prior exposure
to anthracyclines and/or taxanes is a major limiting factor
when selecting such a regimen since it often renders
tumors resistant and is therefore related to reduced clinical
beneﬁts including response rate upon rechallenging to these
chemotherapeutic classes and even to other classes of drugs
[17, 18].
2.1.1. Anthracycline-Based Regimens. With response rates of
up to 60% in previously untreated patients with metastatic
breast cancer anthracycline-based regimens are one of the
most widely used ﬁrst-line chemotherapies. Because of
this advantage patients relapsing more than 12 months
after anthracycline-based treatment may be reinduced
with anthracycline-based combination chemotherapy [19].
Anthracyclines (or anthracycline antibiotics), derived from
Streptomyces bacteria, are a class of drugs widely used and
studied in cancer chemotherapy. Mechanisms of action of
anthracyclines are (1) to inhibit DNA and RNA synthesis
by intercalating between base pairs of the DNA/RNA strand,
thus preventing the replication of rapidly-growing cancer
cells, (2) to inhibit topoisomerase II, preventing the relaxing
of supercoiled DNA, and thus blocking DNA transcription
and replication, and (3) to create iron-mediated free oxy-
gen radicals that damage the DNA and cell membranes.
Anthracyclines-basedcombinationchemotherapyhasshown
improved anticancer activity than anthracyclines alone. For
example, doxorubicin has achieved response rate of 40–50%
as single agent while 60–70% in combination [20]. These
regimens include doxorubicin or epirubicin with cyclophos-
phamide (AC and EC); doxorubicin, cyclophosphamide,
and ﬂuorouracil (FAC or CAF); epirubicin with cyclophos-
phamide and ﬂuorouracil (FEC). Unfortunately, the clinical
beneﬁts of anthracyclines are limited by cardiotoxicity that
can lead to the development of potentially fatal congestive
heart failure [21]. The combination of anthracycline and
cyclophosphamide (AC) is commonly used as ﬁrst-line
chemotherapy in metastatic breast cancer, with or with-
out ﬂuorouracil. Jassem et al. showed improved response
rates of 37% to 57% and median time to progression
ranging from 6 to 9 months for ﬂuorouracil + AC-type
regimens in phase III trials [22]. These regimens are more
active but also more toxic than single agent regimens or
nonanthracycline-based combinations [23, 24]. Joensuu et
al. reported better response rate of 55% in patients treated
with FEC than 48% in patients treated with epirubicin
alone.However,mostofFEC-treatedpatients(80%)suﬀered
from total hair loss while majority of epirubicin-treated
patients (59%) experienced little or no hair loss. Other
chemotherapy-related toxicity were more common in FEC-
treated patients including hematologic toxicity, nausea, and
vomiting [24]. Furthermore, anthracycline-based regimens
havenotdemonstratedabeneﬁtinoverallsurvivalcompared
to single-agent anthracyclines.
2.1.2. Taxane-Based Regimens. Taxanes are another class of
chemotherapy agents originally derived from natural sources
then synthetically derivatized including paclitaxel (Taxol)
and docetaxel (Taxotere). The mechanism of action of
taxanes is to disrupt microtubule function. Microtubules are
essential to cell division, and taxanes stabilize GDP-bound
tubulin in the microtubule, thereby inhibiting the process
of cell division. Therefore taxanes also can be classiﬁedJournal of Drug Delivery 3
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Figure 1: Schematic representation of various combination drug delivery approaches for treatment of cancer. (a) combination of small
molecule chemotherapeutic agents, (b) combination of target speciﬁc biologic agents including monoclonal antibodies, and small molecule
chemotherapeutics (c) carrier-mediated combination drug delivery (see Figures 2 to 5 for structures of various carriers).
as mitotic inhibitors. However due to their poor water-
solubility, taxanes encounter diﬃculties in pharmaceutical
formulation and this often results in reduced bioavailability.
Diﬀerent mechanisms of action of anthracyclines and
taxanesprovidetherationaleofcombinationtherapyofthese
two classes of drugs. Taxanes and anthracyclines typically do
not produce overlapping toxicities with existing therapies.
B r i ae ta l .r e p o r t e di m p r o v e dt i m et op r o g r e s s i o na n do v e r a l l
survival from doxorubicin with paclitaxel (or docetaxel)
therapy compared to anthracycline-based combination ther-
apy (FAC or AC). Although greater hematologic toxicity
(such as neutropenia) occurs from taxane containing regi-
men (74%) than the anthracycline regimen (63%) [18] the
overall added toxicity of an anthracycline/taxane combina-
tion may be overcome by a substantially greater therapeutic
beneﬁt.
Taxane with nonanthracycline combinations is another
highly eﬀective regimen and is particularly useful in patients
with rapidly progressive visceral metastases, who were pre-
viously treated with an anthracycline. In this regimen, cape-
citabine and gemcitabine are drugs of choices as nonanthra-
cycline drugs for combination with taxanes (docetaxel or
paclitaxel). Albain et al. reported the combination of gem-
citabine and paclitaxel regimen to be superior to paclitaxel
alone with longer time to progression (6 versus 4 months)
and better response rate (41% versus 26%). However toxicity
of this combination was higher with increased neutropenia
(61% versus 22%), fatigue (19% versus 13%), and neuropa-
thy (24% versus 22%) [25].
2.1.3. Other Combination Regimens of Nonspeciﬁc Small Mol-
ecule Chemotherapeutic Agents. Increased use of anthra-
cyclines and taxanes in adjuvant (given in addition to
main treatment) and neoadjuvant (given before the main
treatment) settings limits the treatment options for patients
upon relapse. Multidrug resistance (MDR) is a major
limitation of conventional chemotherapy [26]. This is often
a result of overexpression of eﬄux pump proteins such as
P-glycoprotein (P-gp; encoded by MDR1) and multidrug
resistance-associated protein (MRP). Some nonanthracy-
cline and nontaxane-containing multidrug regimens have
high response rates in MDR tumors. For example, ixabepi-
lone is a nontaxane tubulin polymerizing agent that has
low susceptibility to multiple tumor resistance mechanisms.
Preclinical data showed that ixabepilone retains activity
in tumors that use MDR pumps and in tumors that are
paclitaxel-resistant [27]. Ixabepilone in combination with
capecitabine (Table 1) results in prolonged progression-
free survival relative to capecitabine alone (5.8 versus
4.2 months). Objective response rate was also increased
(35% versus 14%). Cyclophosphamide, methotrexate plus
ﬂuorouracil (Table 1), is another combination regimen used
for treatment of metastatic breast cancer.4 Journal of Drug Delivery
Table 1: Clinically used combination regimens of nonspeciﬁc small molecule chemotherapeutic agents in metastatic breast cancer.
Classes Regimens Advantages Disadvantages References
Doxorubicin +
Cyclophosphamide
Anthracycline
based Doxorubicin + Fluorouracil Improved RR
No signiﬁcant diﬀerence in
time to progression or
survival, more treatment
related toxicity, and less
quality of life
[23, 24]
Epirubicin +
Cyclophosphamide
Epirubicin + Fluorouracil
Doxorubicin + Paclitaxel Improved RR and PFS More hematologic toxicity,
cardiotoxicity
[18, 28]
Taxane based Doxorubicin + Docetaxel
Capecitabine + Docetaxel Improved TTP, RR,
and OS
Increased nonhematologic
toxicity (diarrhea,
stomatitis, hand-foot
syndrome)
[25, 29, 30]
Gemcitabine + Paclitaxel
Other
combinations
Ixabepilone + Capecitabine
Improved RR and
TTP in heavily
pretreated patient
Peripheral neuropathy [27]
Cyclophosphamide +
Methotrexate +
Fluorouracil
Improved RR, RFS,
and OS Rapid bone loss [31–33]
OS: overall survival; PFS: progression-free survival; RFS: relapse-free survival; RR: response rate; TTP: time to progression.
As discussed above most combination therapies with
small molecule chemotherapeutic agents present improved
clinical beneﬁts including enhanced response rate and pro-
longed overall survival, progression-free survival, relapse-
free survival, and/or time to progression. However, with
additive eﬃcacy the adverse eﬀects from each agent are
compounded resulting in patients’ suﬀering from more
treatment-related toxicity. The nonspeciﬁc nature of small
molecule chemotherapeutics accounts for much of the
toxicity due to nonselective biodistribution in healthy tis-
sues concurrently with tumor accumulation. Additionally
exposure to multiple conventional chemotherapeutic agents
reduces response rate due to increased eﬄux of these drugs
out of the cells mediated by the overexpression of MDR
related eﬄux pumps or transporters [26]. Therefore, the
need for reducing treatment-related toxicity and overcoming
MDR leads researchers to explore new classes of target-
speciﬁc anticancer therapy.
2.2. Combination of Target-Speciﬁc Biologic Agent and Small
Molecule Chemotherapeutic Agent. Small molecule chemo-
therapeutic agents lack cancer cell-speciﬁc targeting ability
and also aﬀect the fast-dividing normal cells of the body
(such as blood cells and the cells lining the mouth, stomach,
and intestines). Therefore, the major adverse eﬀects from
these chemotherapeutic agents are nonspeciﬁc toxicities
including anemia, nausea, vomiting, and hair loss. Biologic
agents are advantageous to chemotherapy in their ability to
actively target-speciﬁc receptors. Conventional chemother-
apy does not discriminate eﬀectively between tumor cells
and rapidly dividing normal cells thus leading to nonspeciﬁc
adverse eﬀects. In contrast, target-speciﬁc anticancer thera-
pies interfere with molecular targets that have an important
role in tumor growth or progression distinct from normal
cells. Also some of these agents act as inhibitors to MDR-
related proteins thereby increasing the response rate [34].
Overall targeted therapies provide a broader therapeutic
window with less toxicity and higher response rate compared
toconventional chemotherapy.Theyareoftenusefulin com-
bination with chemotherapy (Figure 1(b)) and/or radiation
to produce additive or even synergistic eﬀects with unique
mechanism of action than traditional cytotoxic therapy.
Target-speciﬁcanticancertherapeuticagentscanbeclassiﬁed
by their structures and mechanism of actions as extracellular
targeting monoclonal antibodies and intracellular targeting
small molecular tyrosine kinase receptor inhibitors. These
agents used in metastatic breast cancer target primarily
human epidermal growth factor receptor type 2 (HER2),
vascularendothelialgrowthfactorreceptor(VEGFR),orepi-
dermal growth factor receptor (EGFR). Currently available
target-speciﬁcanticanceragent-basedcombinationregimens
are listed in Table 2.
2.2.1. Monoclonal Antibody-Based Combination Regimens.
Monoclonalantibodies aremonospeciﬁcantibodies madeby
identical immune cells as clones of a unique parent cell. DueJournal of Drug Delivery 5
Table 2: Clinically used combination regimens of target speciﬁc biologic agent(s) in metastatic breast cancer.
Classes Regimens Advantages Disadvantages References
Trastuzumab + Doxorubicin +
Cyclophosphamide Improved RR, PFS, and OS Cardiomyopathy, hematologic
toxicity
[41, 42]
Trastuzumab + Epirubicin +
Cyclophosphamide
mAb based
Trastuzumab + other
chemotherapy (Paclitaxel,
Docetaxel, Vinorelbine,
Capecitabine, Platinum
compounds, and Gemcitabine)
Improved RR and PFS Increased hematologic toxicity [43]
Bevacizumab + Paclitaxel Improved PFS
More toxicity (hypertension,
proteinuria, bleeding, nasal
septum perforation,
thromboembolic event, heart
failure, mortality)
[44]
Cetuximab + Cisplatin Improved RR and PFS in
patients with TNBC
More acne-like rash,
neutropenia, dyspnea
[38]
Lapatinib + Capecitabine
Lapatinib + Paclitaxel Improved RR, TTP, PFS
More toxicity (toxicity from
chemotherapy plus diarrhea,
skin rash, nausea, pruritis)
[45–47]
Tyrosine kinase
inhibitor based Lapatinib + Letrozole
Sunitinib + Docetaxel No worsen toxicity Nonsigniﬁcant combination
activity
[48]
Erotinib + Cisplatin +
Gemcitabine Well tolerated No survival beneﬁt [49]
PARP inhibitor
based
Iniparib + Gemcitabine +
Carboplatin Improved PFS and OS
Neutropenia,
thrombocytopenia, anemia,
fatigue or asthenia, leukopenia
[50]
Olaparib + Gemcitabine +
Carboplatin Improved RR [51]
Multiple
targeted Trastuzumab + Lapatinib Improved PFS and
Overcome TRZ resistance
Additive toxicity from TRZ
and Lapatinib, patient
compliance issue (IV and oral
administration)
[52]
O S :o v e r a l ls u r v i v a l ;P F S :p r o g r e s s i o n - f r e es u r v i v a l ;R F S :r e l a p s e - f r e es u r v i v a l ;R R :r e s p o n s er a t e ;T T P :t i m et op r o g r e s s i o n ;T R Z :t r a s t u z u m a b .
to their nature monoclonal antibodies can be designed to
bind to speciﬁc substances hence they are widely used for
target speciﬁc detection or puriﬁcation [35]. Approximately
20% of breast cancers overexpress HER2, a transmembrane
glycoprotein receptor with tyrosine kinase activity. Overex-
pression of this receptor is associated with increased disease
recurrence and poor prognosis. Trastuzumab (TRZ) is a
monoclonal antibody that interferes with the HER2 by
several suggested mechanisms of action including (1) inhibit
HER2 dimerization, which is essential for further signal
transduction (2) reduce available HER2 on the cell surface
by endocytosis and (3) introduce antibody-dependent cell-
mediated cytotoxicity [36]. The combination of HER2-
directed therapy with endocrine therapy is a promising ﬁrst-
line treatment for patients with hormone receptor-positive
and HER2-positive metastatic breast cancer that is not
imminently life-threatening or symptomatic. For others, the
combination of chemotherapy with HER2-targeted therapy
in the ﬁrst line setting is preferred. Several chemotherapeutic
agents appear to be synergistic with trastuzumab (TRZ)
(Table 2). Robert et al. reported that TRZ plus multiagent
combination chemotherapy (e.g., TRZ plus paclitaxel, and
carboplatin) improves response rates and progression-free
survival, although it also increases toxicity over TRZ plus
single-agent chemotherapy.
Bevacizumab, a monoclonal antibody against VEGFR,
acts as an inhibitor of angiogenesis. VEGF is an important
signalingproteininvolvedinbothvasculogenesis(theforma-
tion of the circulatory system) and angiogenesis (the growth
of blood vessels from preexisting vasculature). Since angio-
genesis is the essential way of providing nutrition to tumors
and a fundamental step in the transition of tumors from
a dormant state to a malignant one, it serves as important
target for anticancer therapy. As monotherapy in metastatic
breast cancer, it has only modest activity (response rate of
9%) [37]. However, Baselga et al. found that bevacizumab
incombinationwithweeklypaclitaxelimprovesprogression-
free survival in HER2-negative disease [38].6 Journal of Drug Delivery
Cetuximab is a monoclonal antibody that targets over-
expressed EGFR in various cancers [39]. EGFR is the cell-
surface receptor for members of the epidermal growth factor
family. Mutations aﬀecting EGFR expression or activity
could result in cancer. EGFR is the most well-known protein
overexpressed among triple-negative breast cancer (i.e., lack-
ing expression of the estrogen receptor (ER), progesterone
receptor (PR), and HER2 proteins). Although single-agent
activity of cetuximab in refractory metastatic breast cancer
is limited, cetuximab combined with cisplatin has shown
modest activity in patients with triple-negative metastatic
breast cancer [38].
Monoclonal antibodies as biologic anticancer agents
have shown reduced toxicity while having modest activities.
The low response rates due to drug resistance can explain
such modest activities. TRZ resistance is developed in
about 70% of TRZ-treated breast cancer patients in early
treatment period [36] and only small portion of patients
(less than 20%) achieved an objective response on cetuximab
treatment [40]. The mechanisms of resistance development
of monoclonal antibody drugs are not fully understood but
mutation on the targeting receptors can explain a part of
the mechanisms. To reduce these anticancer drug resistances
broader targeting and non-MDR aﬀecting small molecule
agents are considered in combination with antibody-based
biologics.
2.2.2. Small Molecule Tyrosine Kinase Receptor Inhibitor-
Based Combination Regimen. Lapatinib is a small molecule
dual tyrosine kinase receptor inhibitor of EGFR and HER2
that, like TRZ, has demonstrated a signiﬁcant improve-
ment in overall survival when added to the treatment of
HER2-positive metastatic breast cancer [53]. The bene-
ﬁt of lapatinib combined with chemotherapeutic agents
(Table 2) as compared to chemotherapeutic agents alone
was seen in patients with progressive, HER2-overexpressing
metastatic breast cancer who were previously treated with an
anthracycline, a taxane, and TRZ. Cameron et al. reported
that patients treated with combination of lapatinib and
capecitabine showed improved overall survival time of 75
weeks compared to that of 64.7 weeks in the patients treated
with capecitabine [45]. However due to the broad selectivity
of lapatinib, the primary observed toxicities of lapatinib are
nonspeciﬁc such as diarrhea, acneiform skin rash, nausea,
and pruritus [47].
Another strategy for targeting VEGF and tumor angio-
genesis is the use of small molecule tyrosine kinase receptor
inhibitors that target the VEGF receptor (VEGFR), including
sunitinib, sorafenib, axitinib, and pazopanib. Gianni et al.
reported improved response rate of 72% with the docetaxel
plus sunitinib combination compared to 11% with sunitinib
monotherapy. Most common side eﬀects of sunitinib are
anorexia, fatigue, mucositis, diarrhea, and nausea. However,
the combination was well tolerated and did not signiﬁcantly
worsen the toxicity associated with the chemotherapy alone
[48].
Although these agents, alone or in combination with
chemotherapy and/or other biologics, hold great promise, to
date they have failed to demonstrate signiﬁcant activity
in metastatic breast cancer [54, 55]. Most small molecule
tyrosine kinase receptor inhibitors have dose-related toxicity
such as hepatotoxicity compared to monoclonal antibody
therapy mainly due to less selective distribution.
2.2.3. Poly(Adenosine Diphosphate-Ribose) Polymerase Inhib-
itor-Based Regimen. Poly(adenosine diphosphate-ribose)
polymerase (PARP) is a DNA-binding protein involved
in detection and repair of DNA strand breaks [56]. PARP
inhibitorsareanewandexcitingclassofagentstotreattriple-
negative and BRCA-mutated breast cancer [57]. Cancers
defective in DNA repair, speciﬁcally cancers with mutations
in the breast cancer associated BRCA1 and BRCA2 genes
and triple-negative breast cancer (which shares molecular
and pathologic features with BRCA1-related breast cancers)
appear to be particularly sensitive to inhibition of PARP-1
[58]. Olaparib (AstraZeneca) is an oral small molecule
PARP inhibitor and its clinical evidence of sensitivity
towards BRCA-mutated cancers was reported in a study by
Gien and Mackay [51]. The early data of ongoing clinical
trial by O’Shaughnessy et al. showed promising results of
signiﬁcantly higher response rates (P = 0.02) of patients
receiving olaparib, gemcitabine, and carboplatin compared
to that of placebo and chemotherapy groups [51].
2.3. Combination of Target-Speciﬁc Biologic Agents. Although
notmanyoftheregimensareclinicallyapproved,theconcept
ofcombinationoftwoormoretarget-speciﬁcbiologicagents
is promising (Figure 1(b)). The rationale is to target multiple
molecular pathways that lead to the same signaling cascade
and hence achieve the synergistic eﬀects. For example when
the extracellular domain of HER2 forms a dimer its intracel-
lular tyrosine kinase domain is phosphorylated and down-
stream signaling cascades are turned on which enhances
cancer cell proliferation, prolongation and angiogenesis. By
administering a combination of TRZ and lapatinib [52],
TRZ can target the extracellular domain of HER2 preventing
dimerization while lapatinib can target the intracellular
domain for HER2 blocking the phosphorylation. In this case
both agents target diﬀerent parts of the same receptor and
hence one can expect the same clinical output [36]. Such
dual targeting of HER2 may be synergistic, as suggested by
an ongoing clinical trial in metastatic breast cancer patients
progressing on one or more prior trastuzumab-containing
regimens [59]. The combination therapy resulted in a sig-
niﬁcant improvement in progression-free survival compared
to monotherapy with lapatinib [52]. The combination has
also been shown to inhibit HER family receptors more
completely than trastuzumab alone and has been eﬀective
against trastuzumab resistant tumors [60]. As discussed
above each class of target-speciﬁc agents still has its own
drawbacks such as drug resistance from monoclonal anti-Journal of Drug Delivery 7
bodies and nonspeciﬁc toxicity and lack of selectivity from
small molecule kinase inhibitors.
3. Challenges of CurrentlyUsed Combination
Treatments for Metastatic Breast Cancer
Beneﬁcial therapeutic eﬀectiveness from combination treat-
ment is promising when considering theoretically nonover-
lapping mechanisms of action of each anticancer agent.
However, current combination treatments in metastatic
breast cancer are far from perfect with moderate enhanced
eﬃcacy but additive toxicity as described above. Commonly
these anticancer agents are administered together as a
physical mixture of each agent without pharmacokinetic
modiﬁcation. These agents (free drugs) therefore distribute
are eliminated independently of each other. As a result the
additive eﬀects are seen not only in anticancer activity but
concurrently in adverse eﬀects. Combining molecularly
targeted agents is an improved strategy, but brings added
complications including patient compliance issue. For exam-
ple, in HER2 targeted combination therapy with TRZ and
lapatinib, these two agents have two diﬀerent routes of
administration. TRZ is given intravenously weekly while
lapatinib is administered daily as an oral formulation. Due
to two diﬀerent ways of administration with diﬀerent sched-
ules it is challenging to manage proper pharmacokinetic
and pharmacodynamic proﬁles and virtually impossible to
achieve uniform temporal and spatial codelivery. Storniolo
et al. reported the results of a pharmacokinetic study of
coadministration of TRZ and lapatinib to 27 patients. Serial
blood samples were collected over a 24-hour period after
ingestion of the lapatinib dose and/or the initiation of
the 0.5-hour TRZ infusion. They reported that lapatinib
area under the plasma drug concentration versus time
curve within a 24-hour period after dosing and Cmax were
not signiﬁcantly diﬀerent in comparing the combination
with lapatinib alone. AUC24 and Cmax of TRZ were not
signiﬁcantly diﬀerent when comparing the combination
to trastuzumab alone [61]. However since the courses of
TRZ last almost one year and the possible drug resistance
development from chronic tyrosine kinase inhibitor therapy
are reported it is not simple to apply this short-term result
to chronic combination regimens. Patients would ﬁnd it
diﬃcult to follow the direction which may cause more
frequent oﬃce visits to improve compliance to the regimen
which also increases healthcare costs.
4.CurrentNovel Approachesto
Overcome the Challenges: Carrier-Mediated
Combination DrugDelivery
The challenges discussed above have driven researchers
to investigate novel approaches by incorporating nan-
otechnology with combination anticancer treatment. The
promising hypothesis is that by delivering two of more
drugs simultaneously using a carrier-mediated drug delivery
system the combination system can generate synergistic
anticancer eﬀects and reduce individual drug related toxicity.
However this area of delivering multiple drugs with a single
vehicle remains largely unexplored while most research
eﬀorts focus on single agent delivery systems. Therefore,
here we will review carrier-mediated drug delivery systems
containing multiple anticancer agents for cancer treatment
in general not limited to metastatic breast cancer. Carrier-
mediated drug delivery systems can oﬀer many advantages
over delivery of physical mixture of multiple drugs. The
advantages include (1) prolonged drug circulation half-life
mediated by the carrier, (2) reduced nonspeciﬁc uptake, (3)
increased accumulation at the tumor site through passive
enhanced permeation and retention (EPR) eﬀect and/or
active targeting by incorporation of targeting ligands [62],
(4) predominantly endocytotic uptake with the potential
to bypass mechanisms of multidrug resistance, and (5)
ratiometric dosing, that is, ability to tailor the relative ratios
of each agent based on its pharmacological disposition.
Also a single delivery system carrying multiple drugs in
the same platform can lead to synchronized and controlled
pharmacokinetics of each drug, resulting in improved drug
eﬃcacy, single formulation with improved solubility and
bioavailability, and so forth [63]. When carrier-mediated
systems containing multiple drugs come to fruition as novel
drug delivery systems in general cancer therapy it can also be
adaptedtometastaticbreastcancertreatment,whichrequires
aggressive therapy. Widely investigated carriers for multiple
drug delivery such as liposomes, dendrimers, polymeric
nanoparticles, and water-soluble polymer-drug conjugates
are reviewed below.
4.1. Combination Drug Delivery Systems Based on Lipo-
somes. Liposomes are spherical vesicles composed of one
or more lipid bilayers with a drug containing aqueous core
(Figure 2(a)). Liposomes are one of the most widely used
pharmaceutical carriers with several unique characteristics
such as (1) ability to encapsulate both hydrophilic and
hydrophobic drugs and (2) protecting the encapsulated
drugs from the external environment [64]. Unmodiﬁed
liposomes are rapidly cleared from the blood by phagocytic
cells of the reticuloendothelial system (RES), resulting in
premature degradation and systemic clearance [64]. To
overcome this challenge long-circulating stealth liposomes
have been developed by coating the surface with an inert
and biocompatible polymer such as polyethylene glycol
(PEG). The polymer layer provides a protective shell over
the liposome surface and suppresses liposome recognition
by opsonins, and therefore prevents rapid clearance by the
RES [65]. Several examples of combination drug delivery
systems based on liposomes are listed in Table 3.Z u c k e r
et al. has developed a PEGylated nanoliposome (LipoViTo)
for simultaneous delivery of two chemotherapeutic agents
(topotecan and vincristine) [66]. In mice xenograft studies,
the simultaneous delivery of two agents by the LipoViTo
system altered the biodistribution of each individual drug
in favor of the tumor resulting in >100-fold higher tumor
levels. This ultimately resulted in a higher therapeutic
response (91% tumor suppression) from the dual-drug
liposome formulation, which could not be achieved by either
administering a combination of free drugs (29% tumor8 Journal of Drug Delivery
Table 3: Combination drug delivery systems based on liposomes.
Formulation Therapeutics Indication Status Targeting References
PEG-Liposome Topotecan + Vincristine Brain cancer In vivo Passive
Polymer-caged nanobins
(PCN); Liposome
surrounded by
cholesterol-terminated
poly(acrylic acid)
Cisplatin + Doxorubicin Various cancers In vitro Passive [67]
Liposome Cytarabine + Daunorubicin Acute myeloid leukemia Phase II Passive [71]
Liposome Irinotecan + Floxuridine Colorectal cancer Phase II Passive [72, 73]
Mixture of two Liposomes Irinotecan + Cisplatin Small-cell lung cancer In vivo Passive [74]
PEG-Liposome Quercetin + Vincristine Hormone- and TRZ-insensitive
breast cancer
In vivo Passive [75]
Cationic, anionic
PEG-Liposome siRNA + Doxorubicin MDR-breast cancer In vivo Passive [76]
Liposome 6-Mercaptopurine +
Daunorubicin Acute myeloid leukemia In vitro Passive [77]
Transferrin- (Tf-)
conjugated PEG-Liposome Doxorubicin + Verapamil MDR-leukemia In vitro Active (Tf receptor) [69]
PEG: polyethylene glycol; MDR: multidrug resistant; TRZ: trastuzumab.
Encapsulated
drugs
pH-responsive
polymer
Conjugated
drugs
Protective
layer of PEG
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Figure 2: Combination drug delivery systems based on liposomes. (a) Combination of drugs encapsulated in the hydrophilic core of
liposome (b) polymer-caged nanobin (PCN); liposome-based hybrid system carrying a combination of encapsulated drug and conjugated
drug.
suppression) or liposomal formulations containing only one
drug (38–43%).
Another unique liposomal system is a polymer-caged
nanobin (PCN, Figure 2(b)) developed by Lee et al., which
illustrates the diﬀerent ways to incorporate multiple drugs
in the same liposome such as encapsulation of one drug
and covalent conjugation of the other. PCN comprising of a
doxorubicin- (Dox-) loaded liposomal core and surrounded
by a cisplatin (Pt) conjugated pH-responsive polymer cage
was developed with tunable drug ratios (Pt/Dox) and surface
charge potentials. This dual-agent formulation dramatically
enhanced the overall eﬃcacy of each drug against breast and
ovarian cancer cells at reduced doses. Combination index
and isobologram analysis conﬁrmed higher synergistic drug
eﬀects over a wider range of concentrations compared to
combinationsofeitherthefreedrugsornanopackagedsingle
drugs. The extent of synergism was further dependent on the
individual drug ratios which highlights the importance of
single carrier-mediated combinationdrug delivery platforms
that allow such tunable drug loading. In vitro studies with
the PCN system further demonstrated that during cellular
uptake via endocytosis, the initial drug-combination ratio in
the liposome was preserved [67].
Attaching targeting ligands such as antibodies and pep-
tides to a drug carrier is a widely applied strategy drastically
increasing carrier accumulation in the desired cells, tissues,
and organs.Severalsuchtargeted liposomes havebeen devel-
oped for combination drug delivery applications [68]. Wu etJournal of Drug Delivery 9
al. synthesized and evaluated transferring- (Tf-) conjugated
liposomes coloaded with doxorubicin (Dox) and verapamil
(Ver). The targeted liposome showed high speciﬁcity for
Tf receptor overexpressing cancer cells. Due to the weakly
basic nature of Dox and Ver, it was possible to load both
agentsintoliposomesviaatransmembranepHgradient.The
Dox and Ver coloaded liposome showed threefold increase
in anticancer activity compared to liposomal Dox alone
while concurrently minimizing Ver-related adverse eﬀects
including cardiotoxicity, which typically occur with systemic
administration of Ver [69]. In addition, the combination of
Tf receptor targeting and coencapsulation of Dox and Ver
was highly eﬀective in overcoming MDR in Dox resistant
cells. These results indicate that active targeting plays a
pivotal role in enhancing receptor-mediated endocytosis of
the drug delivery carrier bypassing Pgp-mediated eﬄux and
resistance mechanisms.
As with any carrier-mediated codelivery system, determi-
nation of the optimal dose as the relative ratio of multiple
drugs is a complex aspect in liposome-based combination
drug delivery system. Mayer et al. reported precise control
over combinatorial drug dosing in liposomes [70]. The
combination of drugs loaded into liposomes at desirable
ratios could be achieved by adjusting liposome synthesis and
drug encapsulation process. Various products based on this
formulation such as CPX-351 (cytarabine + daunorubicin)
[71] and CPX-1 (irinotecan + ﬂoxuridine) [72] are currently
investigated in clinical trials.
4.2. Combination Drug Delivery Systems Based on Dendrim-
ers. Dendrimers are well-established three-dimensional,
branchedpolymersthathavebeenthoroughlyinvestigatedas
controlled and targeted drug delivery systems. The structure
of dendrimers can be deﬁned by an initiator core and layers
of branched repeating units (each layer is called generations)
with functional end groups on the outmost layer (Figure 3).
Dendrimers diﬀer from conventional polymers, in that they
are nanoscopic in size (1–100nm), well deﬁned, spherical,
possess a high degree of molecular uniformity, and bear
ample number of modiﬁable surface groups [82]. The
structural conﬁguration of dendrimers also confers a large
drug loading by various techniques such as adsorption to the
surface (ionic interaction), encapsulation within hydropho-
bic microcavities inside branching clefts or direct covalent
conjugation to the surface functional groups. These unique
properties make dendrimers a desirable platform for concur-
rent delivery of water-soluble and -insoluble drugs [14, 104].
Examples of dendrimer-based combination drug delivery
systems that are currently investigated are listed in Table 4.
For example, Ren et al. have developed a poly (amidoamine)
(PAMAM) dendrimer for simultaneous co-delivery of gene
therapy and chemotherapy agents. 5-ﬂuorouracil (5-FU)
was encapsulated in the cavities of the dendrimer core
via hydrogen bonding while an antisense microRNA (miR-
21) was complexed to the surface through cationic surface
charge-based interaction [78]. Successful synchronous deliv-
ery of the two therapeutic agents was achieved resulting
in synergistic anticancer eﬃcacy, apoptotic activity, and
decreased migration ability of the cancer cells compared to
each agent alone. In another example Kaneshiro and Lu
developed a targeted nanoglobular dendrimer based on a
poly(l-lysine) core for intracellular codelivery of doxorubicin
(Dox, chemotherapeutic) and siRNA (nucleic acid) [81].
An endothelial targeting peptide c(RGDfK) was conjugated
to the dendrimer surface via a PEG spacer. Dox was
covalently conjugated while siRNA was complexed to the
dendrimer. The targeted dendrimer dual agent delivery sys-
tem resulted in signiﬁcantly higher gene silencing eﬃciency
in U87 glioblastoma cells than dendrimer-Dox conjugates
or dendrimer siRNA complexes [81]. Lee and coworkers
have developed a targetable dendrimer for combination
chemoimmunotherapy delivery. A single-stranded DNA-A9
PSMA (prostate-speciﬁc membrane antigen) RNA aptamer
hybrid was conjugated to a PAMAM dendrimer as the
tumor targeting moiety. This system was complexed with
a plasmid bearing unmethylated CpG that acts as both an
immune-stimulating agent and a carrier of the drug, Dox.
The dendrimer-based conjugate showed greater antitumor
eﬃcacy with much lower toxicity than the same dose of free
Dox or aptamer-free dendrimer conjugate in murine tumor
models [79].
4.3. Combination Drug Delivery Systems Based on Polymeric
Nanoparticles. Polymeric nanoparticles are submicron-sized
aggregate structures (3–200nm) that are prepared using
random or block copolymers. Polymeric nanoparticles are
widely used as drug delivery carriers where the active drug
may be physically encapsulated or covalently bound to the
polymer matrix depending upon the method of preparation.
Several polymeric nanoparticle systems have been explored
speciﬁcally for combination drug delivery in cancer using
both passive and active targeting strategies (Table 5).
For example nanoparticles comprising of hydrophobic
copolymerssuchaspoly(lactic-co-glycolicacid)(PLGA)[92]
and polyalkylcyanoacrylate (PACA) [93] have been used to
coencapsulate chemotherapeutic agents and MDR inhibitors
for delivery to various cancers. Polymeric nanoparticles
can also be formed by self-assembly of amphiphilic block
copolymers resulting in a micellar core shell structure. Such
a block copolymer typically consists of a hydrophilic or ionic
copolymer block and a hydrophobic block that can be a
copolymer or a lipid (Table 5). For example, nanomicelles
based on diblock copolymers such as PEG/PLGA or
PEG/PLA have been used to coencapsulate or conjugate
several combinations of anticancer drugs [83–86]. Zhu et
al. described a biodegradable cationic nanomicelle based on
a triblock copolymer of poly(N,N-dimethylamino-2-ethyl
methacrylate)-polycaprolactone-poly(N,N-dimethylamino-
2-ethyl methacrylate) (PDMAEMA-PCL-PDMAEMA). The
hydrophobic anticancer drug paclitaxel was encapsulated
in the micellar core while siRNA was simultaneously
complexed to the outer hydrophilic PDMAEMA shell of
the micelle [87]. Micellar nanoparticles have also been
developed using hybrid block structures such as polymer-
lipid blocks for example, PEG-b-[distearoylphosphatidyl
ethanolamine] (DSPE) [88, 89], PEG-b-[(cholesteryl oxo-10 Journal of Drug Delivery
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Figure 3:Combinationdrugdeliverysystemsbasedondendrimers:concurrentdeliveryofwater-solubleand-insolubledrugsbyadsorption
to the surface (ionic interaction), encapsulation within hydrophobic microcavities inside branching clefts or direct covalent conjugation to
the surface functional groups.
Table 4: Combination drug delivery systems based on dendrimers.
Carrier composition Therapeutics Indication Status Targeting References
G5 PAMAM dendrimer Antisense-miRNA21 +
5-FU Glioblastoma In vitro Active; miRNA
overexpression
[78]
Aptamer-G4 PAMAM
dendrimer conjugates
Unmethylated
CpG-ONTs +
Doxorubicin
Prostate cancer In vivo
Active; a single-strand
DNA-A9 PSMA, RNA
aptamer hybrid
[79]
Dendritic PEG Paclitaxel + alendronate Cancer bone metastases In vivo Active; Bone
metastasis
[80]
RGDfK-G3 Poly-lysine
dendrimer Doxorubicin + siRNA Glioblastoma In vitro Active; αvβ3 integrin [81]
Folate-G5
poly-propyleneimine
dendrimer with
ethylenediamine core
Methotrexate +
all-trans-retinoic acid Leukemia In vitro Active; folate receptor [82]
PAMAM: poly (amidoamine); PEG: polyethylene glycol; PSMA: prostate-speciﬁc membrane antigen; ONT: oligonucleotides; 5-FU: 5-ﬂuorouracil.
carbonylamido ethyl) methyl bis(ethylene) ammonium
bromide sebacate] (CES) [90], and PEG-b-[poly(N-hexyl
stearate l-aspartamide)] (PEG-b-PHSA) [91].
In general it has been shown that polymeric nanoparti-
cles,comparedtoliposomes,havegreaterstability,controlled
size distribution, more tunable physicochemical properties,
sustained and more controllable drug-release proﬁles, and
higher loading capacity for poorly water-soluble drugs.
While majority of the nanoparticle systems described above
have demonstrated synergistic therapeutic eﬃcacy in both in
vitro and in vivo models some of these studies speciﬁcally
illustrate that synergistic therapeutic eﬀect is primarily due
to the ability to administer two drugs in a tunable mass ratio
with predictable spatial and temporal drug release proﬁles.
For example Sengupta et al. developed a hybrid polymeric
micelle [88] comprising of a nanoscale PEG-phospholipid
block copolymer envelope coating a nuclear PLGA nanopar-
ticle. A chemotherapeutic agent doxorubicin (Dox) was con-
jugated to the nanoparticle while an anti-angiogenesis agent
combretastatin(Com)wastrappedwithinthelipidenvelope.
The antitumor eﬀect of this tailor made combination drug
delivery system was far superior to either physical mixtures
of the drugs, mixtures of single agent micellar formulations
and even liposomal drug formulations. Detailed biological
evaluation showed a good correlation between the spatial-
temporal-drug release kinetics and the pathophysiological
conditions. It was shown that the disruption of the outer
lipid envelope occurred inside a tumor resulting in a rapid
deployment of the anti-angiogenesis agent Com, which
caused vascular collapse and the intra-tumoral trapping
of the nanoparticles. The subsequent slow release of the
cytotoxic drug Dox from the nanoparticle killed tumorJournal of Drug Delivery 11
Table 5: Combination drug delivery systems based on polymeric nanoparticles.
Carrier composition Therapeutics Indication Status Targeting References
Polymer-polymer micellar
nanoparticles
PEG-PLGA Lonidamine + Paclitaxel MDR breast cancer In vivo Active; EGFR [83]
Methoxy PEG-PLGA Doxorubicin + Paclitaxel Various cancer In vitro Passive [84]
PEG-PLA Paclitaxel, Etoposide, or
Docetaxel + 17-AAG Various cancer In vitro Active; HSP90 [85]
PEG-PLA Combretastatin A4 +
Doxorubicin Various cancer In vitro Active; angiogenesis [86]
PDMAEMA-PCL-
PDMAEMA Paclitaxel + siRNA Prostate cancer In vitro Active; VEGF [87]
Polymer-Lipid micellar
nanoparticles
PEG-DSPE/PLGA Combretastatin +
Doxorubicin Lung carcinoma In vivo Passive [88]
PEG-PLA and
PEG-DSPE/TPGS
Paclitaxel + 17-AAG
(HSP90 inhibitor) Ovarian cancer In vitro Active; HSP90 [89]
P(MDS-co-CES) Paclitaxel +
Interleukin-12 or siRNA Breast cancer In vivo Active; Bcl-2 [90]
PEG-b-PHSA Doxorubicin +
Wortmannin Breast cancer In vitro Passive [91]
Nonmicellar polymeric
nanoparticles
PLGA Vincristine + Verapamil Hepatocellular
carcinoma
In vitro Passive [92]
PACA Doxorubicin +
Cyclosporine A Various cancer In vitro Passive [93]
17-AAG: 17-allylamino-17-demethyoxygeldanamycin; EGFR: epidermal growth factor receptor; HSP90: heat shock protein; PDMAEMA-PCL-PDMAEMA:
poly(N,N-dimethylamino-2-ethylmethacrylate)-polycaprolactone-poly(N,N-dimethylamino-2-ethylmethacrylate);PEG:polyethyleneglycol;PEG-b-PHSA:
PEG-block-poly(N-hexyl stearate l-aspartamide); PEG-PLA: polyethylene glycol-poly lactic acid; PEG-DSPE: PEG-distearoylphosphatidyl ethanolamine;
PACA: polyalkylcyanoacrylate; PLGA: poly(d,l-lactide-co-glycolide); P(MDS-co-CES): poly(N-methyldietheneamine sebacate)-co-[(cholesteryl oxocarbony-
lamido ethyl) methyl bis(ethylene) ammonium bromide] sebacate; TPGS: tocopheryl polyethylene glycol; VEGF: vasculature epidermal growth factor.
cells more eﬃciently by increasing its apoptotic potential
(Figure 4).
4.4. Combination Drug Delivery Systems Based on Water-
Soluble Polymer Conjugates. Polymer-drug conjugates are
drug delivery systems in which a drug is covalently bound
to a water-soluble polymeric carrier, normally via a bio-
degradable linker. Such nanoconstructs were ﬁrst pro-
posed in the 1970s [105], developed preclinically in the
1980s [106], and started entering the clinical develop-
ment in the 1990s [107]. Numerous studies are available
on water-soluble polymer-drug conjugates including N-
(2-hydroxypropyl)methacrylamide (HPMA), PEG, dextran,
and polyglutamic acid (PGA) backbones carrying a single
drug entity. Only very recently such backbones have been
extended to carrying multiple drugs for combination ther-
apy. Polymer conjugates-based combination strategies can
be categorized in three groups of (1) polymer-single drug
conjugate plus free drug, (2) polymer-single drug conjugate
plus polymer-single drug conjugate, and (3) single polymer
carrier carrying multiple drugs on the same backbone.
Examples of group 1 include coadministration of PGA
copolymer-paclitaxel plus platinum based chemotherapeu-
tic agents [108] or radiotherapy [109]. Combinations of
HPMA copolymer-Dox conjugate plus HPMA copolymer-
phototherapeuticagentconjugate[110]orPEG-ZnPP(heme
oxygenase inhibitor) conjugate plus PEG-DAO (enzyme)
conjugate [111] are examples of group 2. Examples of group
3 are extremely limited in the literature with only a few drugs
being combined within a single polymeric carrier. While
g r o u p s1a n d2h a v eb e e nr e v i e w e de l s e w h e r e[ 112, 113]
the preset review is focused on the drug delivery system of
combination therapy using a single water soluble polymeric
carrier (Figure 5).
N-(2-hydroxypropyl)methacrylamide (HPMA) is one
example of biocompatible, non-immunogenic, non-toxic
water-solublecopolymersthatcanbetailor-madeforspeciﬁc
combination drug delivery needs [114]. The unique charac-
teristics of HPMA copolymers that allow such combination
delivery approach feasible include: (1) ability to easily tailor
individual drug content in the polymer backbone, (2)
covalent linking of drugs to the side chains of polymers
via enzymatically or hydrolytically cleavable spacers and
(3) ability to vary polymer molecular weight, spacer length
and type to systematically control the spatial and temporal12 Journal of Drug Delivery
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Figure 4: Combination drug delivery systems based on polymeric nanoparticles: (a) micellar polymeric nanoparticle, (b) nonmicellar
polymeric nanoparticles.
Table 6: Combination drug delivery systems based on water-soluble polymer conjugates.
Carrier composition Therapeutics Indication Status Targeting References
HPMA copolymer Aminoglutethimide +
Doxorubicin Breast cancer In vitro Passive [63, 94]
HPMA copolymer Gemcitabine +
Doxorubicin Prostate cancer In vivo Passive [95]
HPMA copolymer Doxorubicin +
Dexamethasone General cancer In vivo Passive [96]
HPMA copolymer TNP-470 + Alendronate Bone metastasis In vivo Active; bone [97]
HPMA copolymer Paclitaxel + Alendronate Bone metastasis In vivo Active; bone [98]
Branched PEG Epirubicin + Nitric
oxide
In vivo Passive [99–101]
Branched PEG Camptothecin + BH3
domain peptide
Iv vivo Active; LHRH [102]
HPMA copolymer Trastuzumab + PKI166 HER2 overexpressed
breast cancer
In vitro Active; HER2 [103]
HER2: human epidermal growth factor receptor type 2; HPMA: N-(2-hydroxypropyl)methacrylamide; LHRH: luteinizing-hormone release hormone.
release of the drugs. The ﬁrst conjugate of this type was an
HPMA copolymer carrying the combination of endocrine
therapy (aromatase inhibitor aminoglutethimide (AGM))
and chemotherapy (Dox), HPMA copolymer-AGM-Dox
conjugate [63]. The drug loading in this conjugate was
approximately 5% w/w for AGM and 7% w/w for Dox and
the drugs were linked via a tetrapeptide linker designed to be
cleaved within the lysosomal compartment of cancer cells.
In model breast cancer cell lines this polymer dual drugs
conjugatewasshowntobemoreactivethanthecombination
of two HPMA copolymer conjugates each carrying a single
drug. A follow on study suggested that such increased
activity could be due to a variety of factors, including
drug release rate, conjugate conformation in solution and
possibly,activationofcertainmolecularpathways(induction
of apoptosis, e.g., downregulation of Bcl-2 protein) [63,
94]. Generally for a polymer conjugate drug system the
biodistribution of the polymer is dependent on its molecular
weight, polydispersity, and solution conformation. Hence it
is easier to more correctly predict the pharmacokinetics of
the individual drugs since they are attached to the same
polymer. Another HPMA copolymer conjugate, carrying
two chemotherapeutic drugs gemcitabine (Gem) and Dox
was developed by Lammers et al. [95] assessed in vivo
and proved being able to deliver the two drugs to tumor
tissue. HPMA-Gem-Dox was more active and less toxic than
the combination of two polymer conjugates each carrying
a single drug, and even more than the combination of
the free drugs. Furthermore, HPMA-Gem-Dox inhibited
angiogenesis and induced apoptosis more strongly than
the controls [95]. Segal et al. recently reported an HPMA
copolymer containing the antiangiogenic drug TNP-470 and
aminobisphosphonate alendronate [97]. Alendronate had
the dual function of a bone targeting moiety and a pharma-
cologically active agent. In vitro this combination conjugate
conﬁrmed its antiangiogenic and antitumor properties and
in vivo caused complete tumor regression in a human
osteosarcoma model [97, 98].Journal of Drug Delivery 13
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Figure 5: Combination drug delivery systems based on water-
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Figure 6: TRZ-STP-PKI166 conjugate.
OthershaveexploredmodiﬁcationsofthePEGbackbone
to conjugate a combination of chemotherapeutic agents.
While unmodiﬁed PEG can only conjugate two drug
moleculesperchain(oneoneachend),Pasutetal.developed
a PEG with a dendritic structure on one end that allowed
coupling of upto 8 nitric oxide (NO) and one epirubicin
(EPI)moleculeperchain[99,100].Invivostudiesconﬁrmed
thatthePEG-NO-EPIconjugatedisplayedanticanceractivity
but was less cardiotoxic [100, 101]. This combination is of
particular interest as EPI and NO induce diﬀerent pharma-
cological responses that are tissue-dependent. In cancer cells,
EPI and NO act synergistically, while in cardiomyocytes NO
counterbalances EPI induced cardio-toxicity [100]. Conju-
gation of both drugs onto a single chain ensured that they
undergo the same body distribution, thus maximizing the
beneﬁts of this combination. A branched PEG polymer was
developed by Minko et al. who synthesized a six-branched
conjugate containing equimolecular amounts of CPT, BH3,
and LHRH. In vitro studies showed that such multidrug-
conjugated systems was almost 100 times more cytotoxic
thanthesingleconjugatesanddisplayedenhancedantitumor
activity in vivo when compared with monotherapy [102].
Ourresearchgrouphasrecentlyproposedanovelcarrier-
mediated combination drug delivery system for HER2 over-
expressing metastatic breast cancer [103]. We synthesized
and characterized a star-shaped semitelechelic (ST) HPMA
copolymer conjugate containing both TRZ and PKI166 (a
smallmoleculetyrosinekinaseinhibitor)covalentlylinkedto
thesamebackbone(Figure 6).Therationalisthatsuchadual
drugs conjugate will target and inhibit the extracellular (via
TRZ binding) and intracellular (via PKI166 binding) kinase
domains of the same HER2 receptors in breast cancer cells.
Using a star-like semitelechelic HPMA copolymer structure,
an antibody molecule can be conjugated to several ST-
HPMA precursors via reactive functional group present only
at one end of the polymer chain. This enables single-point
attachment to the antibody and results in a well-deﬁned
system without cross-linking or branching and narrow
molecular weight distribution. ST-HPMA conjugated to
TRZ and PKI166 have demonstrated improved stability and
bioactivity in HER2 overexpressing breast cancer cell lines.
Our results further indicated that the conjugate contained
suﬃc i e n ta m o u n to fe a c ha g e n t st op r o d u c es y n e r g i s t i c
anticancer activity. The conjugate drug delivery system
was shown to be successfully internalized and localized
within HER2 overexpressing breast cancer cells and further
prolonged the kinase inhibitory activity of TRZ and PKI166.
Polymer conjugated dual drug combination systems such
as the one reported could potentially be more eﬀective in
vivo due to altered biodistribution mediated by the polymer.
The TRZ-STP-PKI166 conjugate therefore appears to be a
promising novel drug delivery system that can deliver a
combination of drugs with diﬀerent mechanisms of action
for molecularly targeted therapy to overcome the limitations
from each individual drug alone (Table 6).
5. Conclusions andFutureDirections
The presence of two or more therapeutic agents on a
single carrier platform oﬀers new therapeutic possibilities
but at the same time poses many new challenges. In
order to identify an appropriate drug combination, it
is necessary to perform thorough biological evaluation
which must be supported by a profound understanding
of the molecular mechanisms involved. Another critical
aspect is the determination of the optimal mass ratio
of each component within a combination drug delivery
system. This requires systematic research investigating the
impact of diﬀerent drug ratios on the biological activity
of the combination delivery systems. Recently a Canadian
pharmaceutical company Celator (http://www.celator.ca/)
has developed a methodical approach to assess diﬀerent
drug ratios within their liposomal technology resulting in
the development of diﬀerent liposomal formulations that
are now being assessed in phase II clinical trials, namely,
CPX-1 (irinotecan: ﬂoxuridine) and CPX-351 (cytarabine:
daunorubicin). Such an approach needs to be extended to
other combination delivery systems such as dendrimers or
polymer-drug conjugates. Determination of the kinetics of
release of each drug in a multidrug combination system14 Journal of Drug Delivery
will be also necessary to determine the optimum ratio as
one drug may aﬀect the release proﬁle of the other drug
and thereby aﬀect activity. Finally clinical development of
these combination products is extremely challenging, due
to developmental costs of designing such complex systems.
However, these combination drug delivery system-based
therapeutics are likely to be perceived by pharmaceutical
companies as novel opportunities to extend the patent lives
compared to current blockbuster drugs.
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